Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : UTHR-a Promising Biotech in the works here? -- Ignore unavailable to you. Want to Upgrade?

To: red_dog who wrote (15)	8/20/1999 7:12:00 AM
From: kendall harmon	Respond to of 66

One of the best traders I know of, Lizard King, bought UTHR yesterday at 20 3/16. Message 11007791 Lizard, with one other trader, runs the supertrader trading room at www.supertraders.com. If I have time later I may post a bit about Lizard. At this time I have no association with him or his site but I do think his interest in this stock is significant--he is a much better trader than I will ever be.

To: red_dog who wrote (15)	8/22/1999 11:24:00 AM
From: kendall harmon	Respond to of 66

UTHR--I am in touch with investor relations and should be able to speak with someone there tomorrow to get a further update on Barcelona. I will post if I get any useful details about which I am hopeful.

To: red_dog who wrote (15)	8/28/1999 3:18:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 66

UTHR--a profile of the presenter of the key paper this Tuesday. For those who know the field it IS a big deal that he is the one presenting. Stuart Rich, M.D. is a Professor of Medicine and Director of the Center for Pulmonary Heart Disease in the Rush Heart Institute. He received his M.D. from Loyola University, completed his Internal Medicine Residency at Washington University in St. Louis, and his Cardiology Fellowship at the University of Chicago. Before coming to Rush in 1996, Dr. Rich was on the faculty and, since 1989, the Chief of the Section of Cardiology at the University of Illinois. Dr. Rich has established himself as a leading investigator in the area of pulmonary hypertension and pulmonary heart disease. He has been instrumental in the development of studies describing the natural history, pathophysiology, and treatment of all types of pulmonary hypertension and the development of prostacyclin as a recently FDA approved treatment. source:http://www.rush.edu/Departments/PulmonaryHeart/Physicians/about.html